Pharmaceutical compositions
The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
1. A pharmaceutical composition, comprising:
(a) amorphous solid dispersion particles having a degree of amorphicity of 100% wherein the particles comprise
(i) a protein kinase inhibitor in an amount of from about 10% by weight to about 70% by weight of the particles;
(ii) at least one polymeric stabilizing and matrix-forming component; and
(iii) at least one pharmaceutically acceptable solubilizer selected from the group consisting of a d-α-tocopherol acid polyethylene glycol 1000 succinate, a PEG-40 hydrogenated castor oil, a PEG-35 castor oil, a PEG-40 stearate, a hard fat, a polyoxylglyceride, a PEG-8 caprylic/capric glyceride, and a poloxamer;
wherein the protein kinase inhibitor is dasatinib, dasatinib hydrate, dasatinib solvate, dasatinib salt, or combinations thereof; and
wherein the at least one pharmaceutically acceptable solubilizer is present in an amount of about 0.5% by weight based on the weight of the particles and solubilizer.
2. The composition of claim 1 , wherein the amount of the protein kinase inhibitor is from about 10% by weight to about 50% by weight of the particles.
3. The composition of claim 1 , wherein the amount of the protein kinase inhibitor is from about 10% by weight to about 40% by weight of the particles.
4. The composition of claim 1 , wherein the amount of the protein kinase inhibitor is from about 10% by weight to about 30% by weight of the particles.
5. The composition of claim 1 , wherein the amount of the protein kinase inhibitor is from about 30% by weight to about 40% by weight of the particles.
6. The composition of claim 1 , wherein the protein kinase inhibitor is dasatinib.
7. The composition of claim 1 , wherein the protein kinase inhibitor is dasatinib hydrate.
8. The composition of claim 1 , wherein the protein kinase inhibitor is dasatinib solvate.
9. The composition of claim 1 , wherein the protein kinase inhibitor is dasatinib salt.
10. The composition of claim 1 , wherein the at least one polymeric stabilizing and matrix-forming component is selected from methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, polyvinylpyrrolidone, polyvinyl acetate phthalate, copolyvidone, crospovidone, methacrylic acid and ethylacrylate copolymer, methacrylate acid and methyl methacrylate copolymer, polyethylene glycol, DL lactide/glycolide copolymer, poly DL-lactide, cellulose acetate phthalate, carbomer homopolymer Type A, carbomer homopolymer Type B, aminoalkyl methacrylate copolymers, and poloxamers.
11. The composition of claim 1 , wherein the at least one polymeric stabilizing and matrix-forming component is selected from the group consisting of hydroxypropyl methylcellulose phthalate, hydroxypropyl cellulose, copolyvidone, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, cellulose acetate phthalate and polyvinylpyrrolidone.
12. The composition of claim 1 , wherein the composition further comprises the at least one pharmaceutically acceptable solubilizer.
13. The composition of claim 12 , wherein the solubilizer is selected from the group consisting of d-α-tocopherol acid polyethylene glycol 1000 succinate and a hydrogenated castor oil.
14. The composition of claim 12 , wherein the solubilizer is distributed to the surface of the particles.
15. The composition of claim 1 , wherein the amorphous solid dispersion comprises a powder.
16. The composition of claim 1 , wherein the particles have an average particle diameter size of less than: (i) about 1000 nm, (ii) about 500 nm, or (iii) about 250 nm.
17. A pharmaceutical composition, consisting of:
(a) amorphous solid dispersion particles having a degree of amorphicity of 100%, where the particles comprise
(i) a protein kinase inhibitor in an amount of from about 10% by weight to about 70% by weight of the particles; and
(ii) copolyvidone; and
(iii) at least one pharmaceutically acceptable solubilizer selected from the group consisting of a d-α-tocopherol acid polyethylene glycol 1000 succinate, a PEG-40 hydrogenated castor oil, a PEG-35 castor oil, a PEG-40 stearate, a hard fat, a polyoxylglyceride, a PEG-8 caprylic/capric glyceride, and a poloxamer
and
(b) an excipient;
wherein the protein kinase inhibitor is dasatinib, dasatinib hydrate, dasatinib solvate, dasatinib salt, or combinations thereof;
wherein the at least one pharmaceutically acceptable solubilizer is present in an amount of about 0.5% by weight based on the weight of the particles and solubilizer.
18. The pharmaceutical composition of claim 17 , wherein the amount of protein kinase inhibitor, based on the total weight of particles, is from about 10% by weight to about 40% by weight.
19. The pharmaceutical composition of claim 17 , wherein the amount of protein kinase inhibitor, based on the total weight of particles, is from about 10% by weight to about 30% by weight.
20. The pharmaceutical composition of claim 17 , wherein the amount of protein kinase inhibitor, based on the total weight of particles, is from about 30% by weight to about 40% by weight.
21. The composition of claim 17 , wherein the amorphous solid dispersion comprises a powder.
22. The pharmaceutical composition of claim 17 , wherein the particles have an average particle size of less than: (i) about 1000 nm, (ii) about 500 nm, or (iii) about 250 nm.
23. The composition of claim 17 , wherein the protein kinase inhibitor is dasatinib.
24. The composition of claim 17 , wherein the protein kinase inhibitor is dasatinib hydrate.
25. The composition of claim 17 , wherein the protein kinase inhibitor is dasatinib solvate.
26. The composition of claim 17 , wherein the protein kinase inhibitor is dasatinib salt.
27. A method of treating proliferative disorder in a patient in need thereof, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 18 .